GlassScriptPhysician profile
Seth J Lichtenstein
NPI 1518310507
$10,310.43
in general payments reported to CMS, 2019-2025
38 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $894 · 2021: $1,515 · 2022: $1,482 · 2023: $2,014 · 2024: $2,074 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,708 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,707.86 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,222.05 | 2020-2025 | Avvigo Guidance System, Watchman Flx, Bodyguardian |
| Amgen INC. | $997.48 | 2019-2025 | Repatha, Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $789.57 | 2020-2025 | |
| Abbott Laboratories | $664.98 | 2019-2025 | Aveir |
| Abiomed | $617.26 | 2019-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $516.48 | 2022-2025 | Camzyos, Eliquis |
| Biosense Webster, INC. | $507.45 | 2022 | |
| Edwards Lifesciences Corporation | $465.75 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $421.63 | 2021-2025 | Affera Mapping System, Endurant Iis |
| Janssen Pharmaceuticals, INC | $412.32 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $408.77 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $346.18 | 2019-2025 | Evkeeza, Praluent |
| Actelion Pharmaceuticals US, INC. | $300.74 | 2019-2024 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $252.54 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.92 | 2021-2024 | Jardiance |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $195.00 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $193.10 | 2021-2024 | Farxiga, Wainua |
| Impulse Dynamics (USA) INC. | $171.61 | 2023 | Optimizer |
| Pfizer INC. | $164.30 | 2020-2025 | |
| Shockwave Medical, INC | $149.21 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $133.27 | 2021 | |
| Scpharmaceuticals INC. | $125.00 | 2023 | |
| Corcept Therapeutics | $115.14 | 2024 | Korlym |
| Novo Nordisk INC | $112.83 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $110.86 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $108.70 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $99.31 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $74.54 | 2023 | Zio Xt Patch |
| Alnylam Pharmaceuticals INC. | $67.27 | 2023 | Amvuttra |
| Heartflow, INC. | $66.65 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.21 | 2021-2023 | |
| Esperion Therapeutics, INC. | $50.25 | 2024-2025 | Nexletol |
| Lantheus Medical Imaging, INC. | $49.85 | 2019-2020 | |
| Abbvie INC. | $35.20 | 2022 | |
| Merck Sharp & Dohme LLC | $30.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $29.56 | 2024 | |
| United Therapeutics Corporation | $27.04 | 2021 | |
| Recor Medical INC | $20.76 | 2024 | Paradise Renal Denervation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Lichtenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.